ALZAI developed a 100% non-invasive, highly sensitive, and low-cost tool capable of population-level risk screening for Alzheimers Disease. ALZAI delivers AI-driven AD risk assessment enabling pre-symptomatic intervention to identify patients at-risk, stratify risk by years, and quantify risk by confidence level. The Proof-of-Concept is complete on over 500,000 real world patients period. ALZAI is designed to address a major unmet need and help rewrite the future of Alzheimer’s Disease.
Alzheimers Disease (AD) is a growing multi-hundred-billion dollar market for treatment ($350B+ in the US alone) as AD is epidemic in senior populations. Every major Pharma company has a product pipeline for AD therapies and prophylaxis ($3.7B+). Early detection and prevention are crucial, which could save healthcare systems trillions of dollars in the future. Today, there are expensive diagnostic tools, there are no population risk-screening tools for AD. ALZAI is exactly that, a highly sensitive screening tool for Alzheimers Disease. ALZAI is addressing this major unmet need for Healthcare Providers seeking quality of care, Insurers and Governments seeking efficiency and prevention and Pharma seeking to save time and expense on clinical trials.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2025
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was ALZAI Health founded?
ALZAI Health was founded in 2025.
What industry is ALZAI Health in?
ALZAI Health operates in Hospitals and Health Care. Find similar Hospitals and Health Care investors on gritt.io.
Where is ALZAI Health based?
ALZAI Health is headquartered in Toronto, Canada.
Find investors for your startup like ALZAI Health
Gritt sends AI-personalised outreach to each investor — from your Gmail
